Medarex falls on ipilimumab data

MEDX was off $2.79 (21%) to $10.56 on Tuesday after reporting late Monday that ipilimumab ( MDX-010) missed the primary endpoint of a best objective response rate of >=10% in the Phase II 008 trial in...